Navigation Links
Vertex Plans to Provide Access to Potential CF Therapy VX-770 for Patients with Critical Medical Need
Date:6/10/2011

BETHESDA, Md., June 10, 2011 /PRNewswire-USNewswire/ -- Vertex Pharmaceuticals Inc. announced a plan to provide VX-770, a CF medicine in development, to people with the G551D mutation who are in critical medical need and may benefit from treatment prior to potential approval of the drug from the U.S. Food and Drug Administration (FDA).

Pending FDA review and approval, Vertex expects to open the program at clinical sites in the United States as early as July.

"We are delighted that Vertex is making VX-770 available to patients through an expanded access program," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. "This underscores Vertex's commitment to do what is right for the CF community."

The company is on track to submit a New Drug Application for VX-770 to the FDA in the second half of 2011.

VX-770 is an oral drug in development that targets the underlying cause of cystic fibrosis.

Results from Phase 3 clinical trials released this year showed that those who took the drug had marked improvements in lung function and other key indicators of the disease, including sweat chloride levels, likelihood of pulmonary exacerbations and body weight.

The CF Foundation worked with Vertex to discover VX-770, and has provided substantial scientific, financial and clinical support throughout the development process.

The Vertex VX-770 drug access program is for people with highly limited lung function and who meet other criteria. For information on eligibility or other details, call Vertex Medical Information at 1-877-634-VRTX (8789).

About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, go to www.cff.org.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
2. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
4. Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting
5. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
6. KemPharm, Inc. Announces Plans to Launch KP106 as First Oral Film Dosage Form for ADHD
7. Amgen Outlines Strategy, Growth Objectives and Capital Allocation Plans
8. China Botanic Pharmaceutical Announces Plans to Switch to Renewable Bio-Fuel - Straw Pellets
9. Generex Plans Rights Offering Upon Approval of Reverse Stock Split and Listing on a National Stock Exchange
10. Qmed Announces Increase in Dedicated Staff as Part of Development Plans for 2011
11. Plans to Overhaul Ambulance Industry Met With Enthusiasm: Online Marketplace for Emergency Medical Services Introduces Largest Selection of Products and Services on the Web
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... , June 8, 2017   Responding to Heath ... and the death of singer Chris Cornell in ... Rights International offers a free online psychiatric ... consumers and families about psychotropic drug risks. ... who died from an accidental overdose, has called for tighter ...
(Date:6/7/2017)... Md. , June 7, 2017  Novavax, Inc., (Nasdaq: ... second of two Phase 2 trials of its RSV F ... of child bearing age have been published in the journal ... publication have been shared in prior scientific conferences). The Company ... in April 2014. Novavax is developing the RSV F Vaccine ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... The Kelahan Agency, a ... to residents of southern New Hampshire, is teaming up with the New Horizons ... and homelessness in the region. , New Horizons for New Hampshire provides a ...
(Date:6/27/2017)... ... , ... Dr. Richard Amato, a respected periodontist in Monroe, CT, ... Implant Center of Connecticut. As part of the renovation, the cutting-edge practice added two ... to improve patient comfort while making it possible for Dr. Amato to provide even ...
(Date:6/27/2017)... ... 2017 , ... East Los Angeles dentist, Ramin Assili DDS , comments ... happens to a woman during pregnancy can have profound effects on a developing fetus, ... on a baby’s long-term health. This study, which was performed at the University of ...
(Date:6/26/2017)... California (PRWEB) , ... June 26, 2017 , ... ... of Male Fertility & Sexual Medicine Specialists, in collaboration with the Fertility Center ... for male fertility care: PESA (percutaneous epidydimal sperm aspiration) and TESA (percutaneous testicular ...
(Date:6/26/2017)... ... , ... LARKR™ , an innovative new smartphone app providing on-demand talk ... to join its online treatment platform. , Launching in just a few days, ... number of people in need nationwide, and to supplement their traditional practices. Joining this ...
Breaking Medicine News(10 mins):